Healthcare

Healthcare sector stocks including pharmaceuticals, biotechnology, and medical devices.

63 articles

Healthcare | RVTY | 5d ago

Revvity Inc. Analysts Maintain Optimism Amidst Market Lagging

Despite RVTY lagging the market, analysts hold a positive outlook for Revvity Inc. Explore the key insights for investors.

Healthcare | ALGN | 5d ago

ALGN Rallies as Wall Street Maintains Favorable Stance

ALGN is experiencing a rally following Wall Street's favorable stance, highlighting improving momentum and supportive analyst sentiment.

Healthcare | GILD | 6d ago

Gilead Sciences Reports Strong Q4, Shares Jump Amid Market Volatility

GILD shares rallied after Gilead Sciences reported strong Q4 earnings, showing resilience in a volatile market. What's next for investors?

Healthcare | MDGL | 6d ago

Wall Street Weighs In on MDGL After Kymera Therapeutics Breakthrough

MDGL faces shifting dynamics as Kymera Therapeutics announces advances in protein degradation therapies that could impact its market position.

Healthcare | XLV | 1w ago

Waters Corporation's Recovery: What It Means for XLV Investors

Waters Corporation's outlook remains positive despite trailing the market, revealing crucial insights for XLV investors looking for growth opportunities.

Healthcare | DOCS | 1w ago

Why Investors Are Watching DOCS After Quarterly Report Misses Expectations

DOCS faces scrutiny after its latest quarterly report miss. Investors need to grasp the implications of these results.

Healthcare | TMO | 1w ago

Decoding Thermo Fisher Scientific's Response to Growing Gene Therapy Demand

TMO is poised to capitalize on the burgeoning demand for gene therapy tools and reagents, significantly impacting Thermo Fisher Scientific's growth strategy.

Healthcare | LLY | 1w ago

Breaking: Eli Lilly Reports Q4 2025 Performance Amid Market Volatility

Eli Lilly's Q4 2025 performance outperformed the Russell 1000, showcasing resilience amid market volatility. What does this mean for LLY's future?

Healthcare | LLY | 1w ago

Eli Lilly Eyes New Highs After Promising Trial Results for Psoriasis

LLY's recent Phase 3b trial results for Taltz and Zepbound could significantly impact its market position. Investors should take note of this development.

Healthcare | HALO | 1w ago

Halozyme Therapeutics Reports Q4 Losses, Sends HALO Shares Higher

HALO shares gained momentum despite a reported loss in Q4 2025. Discover the key factors influencing this market reaction.

Healthcare | HIMS | 1w ago

What HIMS Investors Need to Know About Regulatory Scrutiny Ahead of Q4 Earnings

HIMS faces regulatory scrutiny ahead of its Q4 earnings report, raising questions about future performance. Here's what investors need to know.

Healthcare | HIMS | 1w ago

HIMS Rallies as Acquisition of Eucalyptus Valued at $1.15 Billion

HIMS is making headlines with its $1.15 billion acquisition of Eucalyptus, poised to expand its international reach significantly.

Healthcare | REGN | 1w ago

Regeneron Pharmaceuticals Remains Steady Amid AMD Drug Trial Turmoil

REGN stock held steady while AMD drug trials impacted competitors sharply. Delve into the analysis of Regeneron Pharmaceuticals' performance and outlook.

Healthcare | ISRG | 1w ago

Inside Intuitive Surgical's Growth Prospects: Analysts Remain Bullish

ISRG has underperformed recently, yet analysts remain optimistic about Intuitive Surgical's long-term growth. Key metrics suggest a strong future ahead.

Healthcare | HUM | 1w ago